Aquestive Therapeutics, Inc. announced on January 9, 2026, that the FDA identified deficiencies in their New Drug Application for Anaphylm, which could delay its approval but ongoing review is still in progress. The company believes it has adequate funds, with approximately $120 million in cash as of December 31, 2025, to support its long-term strategies.